AB Science announces publication in The Lancet of phase 3

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
442
AB Science announces publication in The Lancet of phase 3 clinical trial results demonstrating masitinib is effective and well tolerated in the treatment of adult patients with mastocytosis

Paris, 9 January 2017, 8am

AB Science announces publication in The Lancet of phase 3 clinical trial results demonstrating masitinib is effective and well tolerated in the treatment of adult patients with severe indolent systemic mastocytosis

AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in the research, development and marketing of protein kinase inhibitors (PKIs), announced today that results from the pivotal phase 3 (AB06006) study of masitinib in severe indolent systemic mastocytosis were published in The Lancet , one of the most highly regarded and well known medical journals in the world, following peer review. Masitinib is the first drug to demonstrate efficacy in a phase 3 study of adult patients with severe indolent systemic mastocytosis, including the subvariant of smouldering systemic mastocytosis, who are unresponsive to existing, optimal symptomatic treatments 1 .

The paper titled: "Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study" [Lortholary O, et al. Lancet 2017; published online Jan 6

DOI:http://dx.doi.org/10.1016/S0140-6736(16)31403-9], along with associated supplementary material, is accessible from The Lancet website ( www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)31403-9/fulltext ).

Below is the summary of the article published in The Lancet :

  • In this pivotal phase 3 study (AB06006), masitinib administered at 6 mg/kg/day was significantly superior to placebo, as measured by the cumulative 75% response rate until week 24 on the handicaps of pruritus or flushes or depression or fatigue (primary endpoint 4R75%). The 4R75% response was 18.7% for the masitinib treatment-arm versus 7.4% for the placebo treatment-arm (p=0.0076) 1 .  
  • Subgroup analysis in patients with the KIT Asp816Val (D816V) mutation (90% of the population) also showed a significant response in favour of masitinib, with a 4R75% response of 20.2% for masitinib versus 7.4% for placebo (p=0.0316) 1 .  
  • Treatment response was sustained over a period of 2 years 1 .  
  • Safety assessment showed a comparable incidence of adverse events between treatment-arms 1 .  
  • Masitinib is the first drug to show significant therapeutic benefit across a diverse range of symptoms as well as objective markers of mast cell activation in patients with severe indolent systemic mastocytosis 1 .

Based on the phase 3 study results, AB Science filed for registration to the European Medicines Agency (EMA) in April 2016 for masitinib in severe indolent systemic mastocytosis.

Dr Michel Arock from the Ecole Normale Supérieure de Cachan (Paris, France), an expert in mastocytosis commissioned by The Lancet to comment on the published article concluded " These data offer high hopes for masitinib, which could become an attractive alternative to the therapeutic arsenal available for patients with severely symptomatic indolent or smouldering systemic mastocytosis 2 . "

Alain Moussy, Chief Executive Officer of AB Science said " Publication of these pivotal phase 3 data in a prestigious medical journal such as The Lancet marks another important milestone in the path to bring masitinib to patients with severely symptomatic indolent systemic mastocytosis, an indication for which there is currently no registered or established standard treatment and a high unmet medical need. Considering that The Lancet sets extremely high standards for peer review and acceptance, its publication of these data is an indication that Key Opinion Leaders consider masitinib as a potential new treatment option for adult patients with severely symptomatic indolent systemic or smouldering systemic mastocytosis, who are unresponsive to existing symptomatic treatments. "

" The AB06006 study data now published in The Lancet show, for the first time, a new therapy that can substantially reduce severe symptoms associated with indolent systemic mastocytosis, regardless of a patient's c-Kit mutational status " said Professor Olivier Hermine M.D., senior author of the paper, President of the Scientific Committee of AB Science and coordinator of the Reference Center for Mastocytosis (CeReMast, Paris, France). " Study AB06006 successfully achieved its primary and secondary objectives; moreover, both efficacy and safety data indicate a possibility for effective long-term management of this difficult-to-treat condition. This observation is important, given that indolent systemic mastocytosis is a chronic condition that requires lifelong management. Masitinib may therefore be an important new treatment option for these patients ."

[1] Lortholary O, et al. Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study. Lancet 2017; published online Jan 6. DOI:http://dx.doi.org/10.1016/S0140-6736(16)31403-9.

http://www.thelancet.com/journals/lancet/arti...9/fulltext

[2] Arock M. A new therapeutic advance for symptomatic systemic mastocytosis? Lancet 2017; published online Jan 6. DOI:http://dx.doi.org/10.1016/S0140-6736(16)31655-5).

http://www.thelancet.com/journals/lancet/arti...5/fulltext

About The Lancet medical journal

The Lancet is the world's leading independent general medical journal. The journal's coverage is international in focus and extends to all aspects of human health. The Lancet publishes original primary research and review articles of the highest standard. The Lancet is stringently edited and peer-reviewed to ensure the scientific merit and clinical relevance of its diverse content. Drawing on an international network of advisers and contributors, The Lancet meets the needs of physicians by adding to their clinical knowledge and alerting them to current issues affecting the practice of medicine worldwide.

Journal Metrics: The Lancet has an Impact Factor of 44.002 and a 5-Year Impact Factor of 46.119 (2016 Release of Journal Citation Reports®, Thomson Reuters).

About masitinib

Masitinib is a new orally administered tyrosine kinase inhibitor that targets mast cells and macrophages, important cells for immunity, through inhibiting a limited number of kinases. Based on its unique mechanism of action, masitinib can be developed in a large number of conditions in oncology, in inflammatory diseases, and in certain diseases of the central nervous system. In oncology due to its immunotherapy effect, masitinib can have an effect on survival, alone or in combination with chemotherapy. Through its activity on mast cells and microglia and consequently the inhibition of the activation of the inflammatory process, masitinib can have an effect on the symptoms associated with some inflammatory and central nervous system diseases and the degeneration of these diseases.

About AB Science

Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a  class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment in cancers, inflammatory diseases, and central nervous system diseases, both in humans and animal health.

AB Science has developed a proprietary portfolio of molecules and the Company's lead compound, masitinib, has already been registered for veterinary medicine in Europe and in the USA. The company is currently pursuing thirteen phase 3 studies in human medicine in metastatic prostate cancer, metastatic pancreatic cancer, relapsing metastatic colorectal cancer, relapsing metastatic ovarian cancer, first-line GIST, second-line GIST, metastatic melanoma expressing JM mutation of c-Kit, relapsing multiple myeloma, relapsing T-cell lymphoma, severe asthma, amyotrophic lateral sclerosis, Alzheimer's disease and progressive forms of multiple sclerosis. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB).

Further information is available on AB Science's website: www.ab-science.com .

Forward-looking Statements - AB Science

This press release contains forward-looking statements. These statements are not historical facts. These statements include projections and estimates as well as the assumptions on which they are based, statements based on projects, objectives, intentions and expectations regarding financial results, events, operations, future services, product development and their potential or future performance.

These forward-looking statements can often be identified by the words "expect", "anticipate", "believe", "intend", "estimate" or "plan" as well as other similar terms. While AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are difficult to predict and generally beyond the control of AB Science and which may imply that results and actual events significantly differ from those expressed, induced or anticipated in the forward-looking information and statements. These risks and uncertainties include the uncertainties related to product development of the Company which may not be successful or to the marketing authorizations granted by competent authorities or, more generally, any factors that may affect marketing capacity of the products developed by AB Science, as well as those developed or identified in the public documents filed by AB Science with the Autorité des Marchés Financiers (AMF), including those listed in the Chapter 4 "Risk Factors" of AB Science reference document filed with the AMF on November 22, 2016, under the number R. 16-078. AB Science disclaims any obligation or undertaking to update the forward-looking information and statements, subject to the applicable regulations, in particular articles 223-1 et seq. of the AMF General Regulations.

For additional information, please contact:

AB Science

Financial Communication & Media Relations

investors@ab-science.com

Attachments:

http://www.globenewswire.com/NewsRoom/Attachm...d812c35b78

Scroll down for more posts ▼

Top 10 Most Recent News Articles

DarioHealth's New Research Tackles Healthcare Cost Estimation

Updated Category News Views 124

Unpacking Dario's Bold Surgical Strike at ISPOR Europe Alright, folks, DarioHealth is shaking up the stage with their new methodology that could very well carve a new path in how we size up digital healthcare savings. Presented at ISPOR Europe 2026, Dario's tactic bypasses the sluggish wait on medical claims data, instead offering an evidence-driven peek at potential...

Continue Reading
DoGo Power Revamps Energy for Remote Indonesian Isle

Updated Category News Views 131

Bringing Light to Pagerungan Kecil Island These days, if you wander into the fishing communities of Pagerungan Kecil Island, the buzz isn't just from the daily catch. Residents are talking about power, and not the kind you get from a generator spluttering along—I'm talking about a brand-new energy storage system that’s turning the lights on in ways these folks have...

Continue Reading
Mercari and Suruga-ya Forge U.S. Venture for Culture

Updated Category News Views 189

Japanese Pop Culture Gears Up for US Market Surge Alright, folks, what we’ve got here is another bold move in the cross-border e-commerce game. Mercari and Suruga-ya are teaming up to establish a joint venture over in the U.S. The goal? To further capitalize on the growing appetite for Japanese entertainment and hobby goods among us all stateside. Now, it’s no secret...

Continue Reading
SwitchBot's Hub 4: A Step Toward a Connected Future

Updated Category News Views 67

Turning a House Into a Smart Home Haven Out of Tokyo and onto the world stage, SwitchBot's got something new cooking that might just shake up the smart home scene. They've launched the Hub 4, a gadget that's like the Swiss Army knife of home control. For those who like things simple, this is a one-hub-to-rule-them-all kind of deal. 101,000 Reasons to Notice Now, they...

Continue Reading
Sabre Unveils AI Travel Tech: A Bold New Frontier

Updated Category News Views 19

Sabre's Game-Changing AI Travel Integration I'm no stranger to bold moves in the travel industry, but what Sabre's rolling out tomorrow might just be the biggest leap we've seen in a while. They're unleashing what's called the first global travel plug-in within Grok Bot, marking a significant shake-up in the travel tech sphere. Too many tech upgrades in this business...

Continue Reading
XKIG Bolsters Northwest with Jensen's Acquisition

Updated Category News Views 29

Stepping Up the Game in the Pacific Northwest Well, here we see another classic example of a shrewd move in the infrastructure sector. XKIG, a name known to those who keep an eye on critical infrastructure services for utilities, has decided to widen its footprint with a strategic grab of Jensen's Tree Service, Inc. They’re setting up shop even deeper in the Pacific...

Continue Reading
Sharon Stuart's Quest for Her Hidden Origins

Updated Category News Views 55

Delving Into Identity: A Personal Odyssey In a world where everyone seems to be searching for something, Sharon Stuart's quest is etched with the raw need to uncover her real origins. Abandoned as a newborn in the gritty streets of Oakland, she grew up grappling with looming questions about what made her who she is. Her journey is captured in her memoir, "Existing Without...

Continue Reading
Graphic Packaging Shakes Up Leadership and Supply Chain

Updated Category News Views 81

New Leadership Takes the Helm at Graphic Packaging What do you do when you want to streamline an operation that spans continents? Well, if you're Graphic Packaging Holding Company (NYSE: GPK), you bring in fresh leadership to serenade the chaos into a well-oiled machine. Starting December 1, 2026, D. Keith Hamilton will be sinking his teeth into North America Mills &...

Continue Reading
IQSTEL's Nine-Month Revenue Hits $313M, Growth Impresses

Updated Category News Views 107

Pushing Through With Persistence Well, well, well, here we are, talking about IQSTEL Inc. (NASDAQ: IQST) slinging some serious numbers—not the kind you can ignore at your breakfast table. The company pulled in a whopping $313 million in revenue over the first nine months of 2026. That’s a bump up by 34.5% from last year’s $232.7 million. What’s behind the magic...

Continue Reading
Tenax Class Action: Investors Alley Fight for Redress

Updated Category News Views 33

Tenax Therapeutics in Hot Water Over Drug Trial Results Amidst the ever-unpredictable tides of the pharmaceutical industry, here comes a doozy – Tenax Therapeutics, Inc. is neck-deep in a shareholder lawsuit. If you tossed some money at NASDAQ:TENX anytime between November 13, 2023, and August 7, 2026, you might be feeling the sting of regret, and rightly so. What Went...

Continue Reading

Top 5 Most Recently Viewed Articles

Enhancing Enterprise Security Through Browser Integration

Updated Category News Views 280

Enhancing Enterprise Security Through Browser Integration Seraphic recently announced an exciting expansion of its collaboration with the CrowdStrike Falcon platform, a move poised to revolutionize browser-layer security. This integration provides users with an enhanced approach to managing digital threats, bringing powerful visibility and control to browser activities...

Continue Reading
Smirnoff ICE Unveils Exciting New Sunsurance Initiative

Updated Category News Views 433

Introducing Sunsurance from Smirnoff ICE Summer is just around the corner, and with it comes the excitement of sunny days, picnics, and outdoor gatherings. Smirnoff ICE is generating buzz with its latest initiative, Sunsurance, promising to elevate your summer experience. This innovative program is designed to ensure that regardless of what the weather brings, you can...

Continue Reading
First Watch Restaurant Group's Upcoming Conference Engagement

Updated Category News Views 175

First Watch Restaurant Group to Engage at Growth Frontiers Conference First Watch Restaurant Group, Inc. (Nasdaq: FWRG), considered a beacon in the Daytime Dining scene, is set to make its mark at the highly anticipated Piper Sandler’s Growth Frontiers Conference. This event will be held from September 9-11 and will feature a remarkable platform for discussion and...

Continue Reading
Detailed Insight on Rathbones Group Plc's Recent Disclosures

Updated Category News Views 111

Overview of Rathbones Group Plc's Key Disclosures Rathbones Group Plc has recently made significant public disclosures regarding its shareholding and investment positions in relation to De La Rue Plc. These disclosures are pivotal as they provide insights into the company’s financial dealings and interests in relevant securities, particularly those representing 1% or...

Continue Reading
Stride, Inc. Faces Class Action Lawsuit Over Alleged Fraud

Updated Category News Views 180

Class Action Lawsuit Against Stride, Inc. In recent developments, leading securities law firm Bleichmar Fonti & Auld LLP has initiated a class action lawsuit against Stride, Inc. (NYSE: LRN) for alleged securities fraud. This lawsuit follows significant stock price declines attributed to potential violations of federal securities laws. The Nature of the Allegations...

Continue Reading